RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer. [PDF]
Yoshida H +4 more
europepmc +1 more source
1,3-dipolar cycloaddition reactions of triene-conjugated nitrile ylides and diazoalkanes [PDF]
Cessford, Alastair G.
core
Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51. [PDF]
Huang L +5 more
europepmc +1 more source
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. [PDF]
Li C +27 more
europepmc +1 more source
Impact of Olaparib, Niraparib, Rucaparib therapies on Newly Diagnosed and Relapsed Ovarian Cancer -Systematic Review and Meta-Analysis. [PDF]
Devi S, Chandrababu R.
europepmc +1 more source
FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response. [PDF]
Banerjee M +14 more
europepmc +1 more source
PARP Inhibition Shifts Murine Myeloid Cells Toward a More Tolerogenic Profile In Vivo. [PDF]
Pittaluga-Villarreal JR +5 more
europepmc +1 more source
Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching. [PDF]
Liu C +15 more
europepmc +1 more source
Shared and non-overlapping functions of RECQL4 and BLM helicases in chemotherapeutics-induced glioma cell responses. [PDF]
Wojnicki K +6 more
europepmc +1 more source

